Faecal occult blood screening for colorectal cancer: is it cost‐effective?

David K. Whynes, Aileen R. Neilson, Andrew R. Walker and Jack D. Hardcastle

Health Economics, 1998, vol. 7, issue 1, 21-29

Abstract: Recently published evidence from two large‐scale clinical trials conducted in England and in Denmark suggests that faecal occult blood screening for colorectal cancer significantly reduces mortality. However, before screening can be advocated as part of national health policy, its cost‐effectiveness must be demonstrated. The English screening trial has been the subject of a detailed economic evaluation over the past 10 years. In this paper, cost‐effectiveness estimates of screening are presented, based on cost and outcome data combined in a mathematical model developed from the trial's clinical findings. The estimates of cost per quality‐adjusted life‐year gained from colorectal cancer screening show the procedure to be of similar cost‐effectiveness to breast cancer screening in the short term. Over the longer term, however, the estimates for colorectal cancer screening appear superior. © 1998 John Wiley & Sons, Ltd.

Date: 1998
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://doi.org/10.1002/(SICI)1099-1050(199802)7:13.0.CO;2-9

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:7:y:1998:i:1:p:21-29

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().